Home › Trials › NCT06830759

Assessing Epcoritamab for Adult Patients with Advanced Lymphoma

EpcoReal: A Multi-country, Prospective Observational Study of Epcoritamab in NHL Comprising Two Patient Cohorts (3L+ (D)LBCL and 3L+ FL)

AbbVie · NCT06830759

This study is testing if a new skin injection called epcoritamab can help adults with advanced lymphoma feel better and improve their health.

Quick facts

Study typeObservational
Enrollment700 (estimated)
Ages18 Years and up
SexAll
SponsorAbbVie (industry)
Drugs / interventionsepcoritamab
Locations73 sites (Ciudad Autonoma de Buenos Aire, Buenos Aires and 72 other locations)
Trial IDNCT06830759 on ClinicalTrials.gov

What this trial studies

This study evaluates the real-world effectiveness of subcutaneous epcoritamab in adults diagnosed with advanced diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Approximately 700 participants will be enrolled across 80 sites in 12-20 countries, receiving treatment as prescribed by their physicians. Participants will be monitored for up to three years, attending regular visits at their healthcare facilities without additional burdens related to the study.

Who should consider this trial

Good fit: Ideal candidates are adults with advanced DLBCL or FL who have undergone two or more prior lines of therapy.

Not a fit: Patients who are not eligible for epcoritamab treatment or are participating in concurrent interventional clinical trials may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide insights into the effectiveness of epcoritamab, potentially improving treatment options for patients with advanced lymphoma.

How similar studies have performed: While this study focuses on real-world effectiveness, similar studies assessing investigational drugs for lymphoma have shown promising results, indicating potential for success.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Participants who are scheduled to be treated with epcoritamab for Treatment after two or more prior lines of therapy 3L+ diffuse large B-cell lymphoma ((D)LBCL) or 3L+ Follicular lymphoma (FL).
* Treatment with epcoritamab should be administered in accordance with the approved local label in the participating country.
* The decision to treat the participant should have been made by the clinician prior to, and independently of any decision to approach the participant to participate in this study.

Exclusion Criteria:

* Any condition included in the contraindications section of the approved local epcoritamab label in the participating country.
* Participation in a concurrent interventional clinical trial (not including non-interventional/ observational study, PMOS, or registry participation) from enrollment and throughout the study.

Where this trial is running

Ciudad Autonoma de Buenos Aire, Buenos Aires and 72 other locations

+23 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Diffuse large B-cell lymphoma, Epcoritamab

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.